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Among the symptoms of COVID-19 fever, general malaise, pain and aches, myalgia,
fatigue, and headache can affect the quality of life of patients, even after the end of the
acute phase of the infection and can be long lasting. The current treatment of these
symptoms, also because COVID-19 patients have been asked not to use non-steroidal
anti-inflammatory drugs (NSAIDs), in particular ibuprofen are often unsatisfactory. Among
the above mentioned symptoms malaise and fatigue seem the most difficult to treat. In
this case report we describe the use of kratom (Mitragyna speciosa) by a patient with
confirmed COVID-19 infection. What we observed was a fast and sustained relieve of
the above mentioned symptoms.
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BACKGROUND
Viral infections, including the current COVID-19 pandemic, are often associated with fever, general
malaise, pain, and aches (1, 2). Of these, fever (98%), cough (76%), dyspnoea (55%), myalgia or
fatigue (44%), headache (8%), and haemoptysis (5%) are commonly noted (2). These infections,
therefore, even in the milder and non-life threatening forms, can significantly affect the quality
of life. Among the various peculiarities of the COVID-19 infection concerns have been raised
about the use of non-steroidal anti-inflammatory drugs (NSAIDs), in particular ibuprofen, which
at first seemed to worsen the illness, although further studies have disproved this concern (3). As a
consequence, several regulatory agencies, including the EuropeanMedicines Agency (EMA), at first
expressed concerns about its use, as it may deprive patients of an effective treatment for fever and
pain with the exception of paracetamol/acetaminophen (3). The debate about NSAID safety is still
open. At the beginning of the pandemic, ibuprofen was hypothesized to increase the risk of severe
adverse events in COVID-19 patients and a link between NSAIDs and angiotensin-converting
enzyme (ACE) 2 receptors upregulation was suggested to be involved (4). Further, Micallef
et al. (5) reported that some preclinical evidences, such as immunomodulatory effects or
antibiotics efficacy reduction, would support a possible link between NSAIDs and complications
in COVID-19 patients. However, data about NSAIDs use in COVID-19 is still inconsistent. In
fact, some authors suggested that NSAIDs should be avoided in COVID-19 (6, 7) and others
reported that NSAID use has been associated with worse outcomes (4). At the same time, other
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authors highlighted that evidence about the worsening of
COVID-19 symptoms by ibuprofen is lacking (8, 9) or only
suggested to be prudent in the prescription (10).
Up to date it is possible to say that there is not an unique point
of view and the controversial NSAIDs use in COVID-19 is still
discussed (8), with recently a positive insight on ibuprofen in
COVID-19 disease (11). As consequence there has been a drop
in ibuprofen sales (as reported by Glaxo Smith Kline–GSK) in
the second quarter of 2020 (12). Considering the burden that
COVID-19 infection is imposing to the world population (both
in the acute phase and in the so called “long COVID”) we thought
important, therefore, to consider also other treatments that could
expand our pharmaceutical armamentarium that could alleviate
the symptoms of COVID-19 Infection.
In this case report we describe the use of kratom (Mitragyna
speciosa), a plant used in traditional medicine in South-
East Asia for its therapeutic benefits in self-managing opioid
dependence and withdrawal, psychological disorders (e.g.,
anxiety and depression), and chronic pain (13, 14), and to
successfully alleviate COVID-19 related symptoms. Kratom
contains more than 40 alkaloids (15, 16), though the majority
of its pharmacological properties appear to be related to
two of the active compounds: mitragynine and its metabolite
7-hydroxymitragynine (17–19). Kratom is reported to have
opioid and non-opioid like effects. In traditional settings in
Malaysia and Thailand, rural folks traditionally use kratom
as a remedy to treat common health maladies, and kratom
consumption practice/tradition do not seem to cause any
significant health problems (20–22).
The results of several anonymous online surveys have
indicated that the use of kratom products may be useful for
the self-treatment of acute and chronic pain (23–25), and in
fact, its use is only self-reported to be associated with few
adverse effects. Findings from a recent clinical trial confirmed
the analgesic properties of kratom in healthy volunteers lasting
for approximately 2 h with average blood concentrations of
mitragynine at 2,000 ng/mL (26). These results suggest that
kratom has the potential to be used as a centrally acting
herbal analgesic.
Although kratom is reported to be used as a safe substitute
to opioids in self-managing pain, dependence and withdrawal
(23–25), it is not free from adverse effects and risks. Kratom
dependence has been reported if the product is used in larger
quantity over a prolonged period, and negative effects such as
sleep problems, depressedmood, diarrhea, and flu-like symptoms
including muscle and joint pain can develop with sudden
withdrawal (27). Fatalities involving kratom are rare and, autopsy
findings indicate that in such instances kratom is concurrently
used with illicit substances or anti-depressants, and not kratom
per se, or the user had an underlying health condition (28, 29).
So far, there have been no reports specifically on fatal kratom
overdose incidences (30).
We are aware, however, that there is a lack of robust
data about kratom efficacy in humans, to the best of our
knowledge there is only one randomized controlled trial that
would give some support to kratom’s therapeutic potential in
pain. Most of the information available today are the results
of surveys and of retrospective studies, in which users claim
Kratom’s efficacy in treating acute and chronic pain of different
etiologies (23, 24). Other conditions that appear to benefit from
kratom are headache (24, 25), back, neck and muscle pain
(24, 25), fibromyalgia, arthritis (including autoimmune ones
like rheumatoid arthritis), autoimmune disorders like multiple
sclerosis (13, 25), and other severe conditions like cancer
and chronic inflammatory diseases (25). Some autheors have
therefore speculated that kratom has a role in the Central
Nervous System (CNS) but also as anti-inflammatory (31–33),
muscle relaxant (34).
Despite the potential therapeutic benefit, kratom has also
severe side effects, that should be always considered when
suggesting or only considering a treatment with kratom (35).
Among the most severe side effects have been described
kratom associated hepatitis (36–39), seizures and coma (40, 41),
hypogonadism (42), hypothyroidism (43), posterior reversible
leukoencephalopathy (44), fatalities (29, 45) and overdoses
(46, 47). It is important to underlie, however that most of
these events were described mainly in the US and Europe
(where Kratom was recently introduced), with a majority
of the reported deaths involving the presence of other
substances (29), such as benzodiazepine, opioids, antidepressant
or antipsychotic agents, alcohol or other substances, e.g., Datura
stramonium, cannabinoids, amphetamines (40, 45, 48–51), and
other contaminant such as O-desmethyltramadol (52).
There is growing evidence, however, that kratom is safer if
used as pure kratom products or brewed herbal decoction in
small doses and for a limited period of time. It should be avoided
the consumption of large amounts (more than 15 grams per
dose) and high frequencies (more than 3 times/day for extended
periods of time) because the risk of developing dependence.
Several cases have been reported in both Western (53–55),
including cases of neonatal abstinence syndrome (56, 57), and
Eastern countries (27, 58, 59), where those who used kratom
for a long time experienced both physical (e.g., constipation)
and psychological (e.g., anxiety) withdrawal symptoms. More
recently an article have been published by Muller et al. (60) in
which an individual self-prescribing kratom for pain treatment
reported an escalation of the dosage needed and eventually
developed a dependence.
Considering the conflicting evidence and the paucity of
randomized control studies the balance between kratom benefits
and risks is not clear yet, but some data suggested that kratom
may cause less issues compared to opioids as well as retrospective
data showed that kratom reduced the prevalence opioid adverse
effects in users (24) and among illicit opioid users (61).
CASE REPORT
Case Presentation
The subject of this report is a 29 year old male, US citizen of
Palestinian descent, who works full-time as a biomedical research
technician. His health history is unremarkable, except for the fact
that at age 16 he was diagnosed with ulcerative colitis and primary
sclerosing cholangitis. Since then, he has been treated successfully
with mesalamine (1.2 g, 2 times per day), azathioprine (50mg,
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3 times per day), and ursidiol (300mg, 2 times per day). The
subject has been able to live an active lifestyle and participate
in a variety of sports including running, weightlifting, basketball,
and baseball. The subject denies any history of smoking or use of
alcohol, opioids, or illicit drugs. On April 22, 2020, the subject’s
father, who lives in the same house as the subject, and works
for a major shipping company, was diagnosed with COVID-
19. This was about 2 months after the first case of COVID had
been confirmed in his state of residence, which was one of the
early active zones of COVID-19 transmission in the US. On
April 25, the patient began to experience general malaise and
fatigue. Over the next 24 h, the symptoms worsened to include
severe fatigue and weakness, loss of appetite, tiredness, slight
dry cough, body aches, muscle pain, loss of taste and smell,
sore throat and fever. The patient was then seen by his general
practice physician. Vital signs at the time of examination were
BP 110/72, pulse 97 BPM, respiration 14 per minute, oxygen
saturation 98%, and body temperature 101.7◦F. The patient was
given a naso-pharyngeal swab, real-time RT-PCR test [COBAS
(R) SARS-COV-@ test, Labcorp Laboratories, South Bend, IN]
that confirmed a diagnosis of COVID-19. In compliance with
standard medical practice standards, the patient was ordered to
self-isolate and to start a 5-day course of azithromycin (250mg,
daily), and to also take 1 g of paracetamol (acetaminophen) every
6 h for treatment of pain and fever. Despite good adherence to
the recommended treatment, the symptoms other than fever, did
not improve, and he also started to feel depressed, demotivated,
and spend long periods in bed. During this period, the patient
experienced ongoing generalized myalgia and musculoskeletal
pain. He described the pain as persistent and relatively severe
(rated 7 on a scale of 1–10). Because of this discomfort, after
4 days the patient decided to consume kratom to relieve his
symptoms. According to the patient, he had first used kratom 14
months earlier before his COVID-19 infection. He used kratom
sporadically (no more than 4–5 times in total) as a cognitive
enhancer and not to self-treat pain.
Treatment
The patient decided to take 2.5 gms (or grams) of green kratom
(as ground leaf powder suspended in water). The product was
purchased at a local shop in April 2020 sold under the name
“Green Bali.” After 30min, he noticed a significant improvement
in the intensity of the physical symptoms (mainly pain and
fatigue), and within 60min he felt a sensation of mild euphoria
and well-being that lasted for about 5 h. After 6 h following
consumption the effects of kratom wore off, and the patient
administered another dose. He used kratom three times a day
continuously for 3 days (for a total of 9 doses of 2.75 g each) with
significant benefit.
Outcome
When asked to score from 0 to 100% the improvement that
kratom had on COVID-19 symptoms: fatigue and weakness
(80% improvement), tiredness (70% improvement), body aches
(80% improvement), muscle pain (90% improvement, “much
better than paracetamol/acetaminophen”). The kratom did not
seem to have an impact on: fever, cough, or sore throat. The
patient also stated: “I didn’t have anxiety or any psychological
symptoms. For me, kratommainly gave improvement in physical
reaction.” “It also elevated my mood and made me feel less
miserable, to the point where I was able to get out of bed, shower,
look at work emails without feeling completely exhausted and
drained”; “Kratom helped me more than antibiotic”; “I slept
better, I essentially fell asleep immediately.Without kratom, sleep
was not nice, with kratom less wake ups, about 6 h.” Over the
next 2 weeks the patient’s symptoms gradually subsided and on
May 13 he had a televisit with his physician and a follow-up
swab test that was negative for COVID-19. The subject was able
to end his quarantine and return to work in early June. In a
follow-up interview with us, the patient reported that he did
not experience any side effects from using kratom, except for
a very bad taste when swallowing it. The patient was also able
to discontinue kratom use immediately without any evidence of
physical or psychological withdrawal symptoms. The patient also
informed us that he still had some of the kratom product that
he had taken and he agreed to provide us with a sample for
chemical analysis.
Kratom Sample Analysis
An established quantitative liquid chromatography mass
spectrometry method was conducted (62) and found that
the sample obtained from the patient is kratom due to the
presence of mitragynine (102 mg/g kratom powder) and
7-hydroxymitragynine (0.8 mg/g kratom powder). The extracted
kratom sample was analyzed for the presence of 13 opioids
and 8 benzodiazepines by comparing the chromatograms
to those of the reference mixtures Pain Management Multi-
component Opiate Mixture-13 solution and Benzodiazepine
Multi-component Mixture-8 solution. These data suggest the
sample was not fortified with 7-hydroxymitragynine and there
was also no evidence of adulteration with opioids or common
benzodiazepines in the sample.
DISCUSSION
To the best of our knowledge, this is the first case report that aims
to highlight the use of kratom in alleviating COVID-19 infection
related symptoms, and pain. Our findings show that short-term
kratom use has the potential to alleviate COVID-19 infection
symptoms, primarily pain, and did not seem to cause any
physical and psychological withdrawal symptoms when kratom
was discontinued after short-term use.
Kratom is an evergreen plant indigenous to Southeast Asia.
Historically, kratom is a widely used folk remedy or traditional
medicine. Kratom prominence grew a decade ago in Europe
and the US, when it was chiefly used for its unique medicinal
properties in self-managing pain, infections, opioid dependence
and withdrawal (25, 63).
The antinociceptive action depends on mitragynine
pharmacology: the compound acts as a partial G-protein
biased agonist of mu opioid receptors (64, 65), and also as an
agonist at other receptors (serotonin, adenosine-2a, dopamine-2,
postsynaptic alpha-2 adrenergic) (17, 66). The antinociceptive
effects of mitragynine have been studied in animal models
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(18, 67, 68), and human data, derived mainly from surveys
or retrospective studies in users, clearly shows that kratom is
used for pain relief and to improve mood (23, 24). The exact
dose-response relationship is still unknown, but an average daily
consumption of 76.3–114.8mg of mitragynine (equivalent to 3.5
glasses of kratom tea/ juice) seems to be well-tolerated among
users in traditional settings (69).
COVID-19 is a global emergency, and most of the clinical
trials and research are dedicated to find effective treatments
against the virus and the consequences of the infection. However,
like many other viral and bacterial infections, COVID-19
infection is also associated with pain, aches and malaise and
usually has a negative impact on the quality of life of patients.
The current treatment for these symptoms is based mainly
on paracetamol and/or NSAIDs. These compounds, however,
are not always effective or sometimes should be avoided.
It is necessary therefore to consider alternative and more
effective treatments that can provide immediate reprieve from
COVID-19 infection.
As far as we know, this is the first case report that aims
to indicate the potential benefit of using kratom to mitigate
COVID-19 related symptoms, as well as pain. Previous case
reports mainly reported about the negative effects of kratom
consumption that were linked to adverse events such as
dependence/withdrawal syndrome, hepatic toxicity, seizures (35,
40), and fatalities (29). A majority of the reported cases involve
other substances that cast doubt on the causative contribution
of kratom to the adverse outcome. However, the consumption of
large amounts (more than 15 g per dose) and high frequencies
(more than 3 times/day for extended periods of time) of kratom
is ill advised, and can increase the risk of adverse effects. Adverse
effects are rarely observed with the consumption of pure kratom
products or brewed herbal decoction in different doses and
frequencies among users in traditional settings. Though findings
from numerous studies continue to support kratom’s therapeutic
potential chiefly for pain relieve, at this juncture, there is no solid
scientific evidences to prove its utility. More controlled clinical
studies are needed to identify the pharmacological properties,
safety of kratom doses, and its efficacy with the current standard
treatment for pain relieve.
We think there is a promising scope for future studies in
the field. However, we believe that there is a need for a series
of clinical trials to identify the safe dosage and pharmacology
of mitragynine, monitor, and identify potential side effects of
long-term kratom use, and eventually consider a double blind
randomized clinical trial to compare its efficacy with the present
standard pain relieve treatment.
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